Mast Cell Activation: FcεRI Signalling and Mediator Release
Mast cells (tissue-resident; bone marrow-derived; IgE-FcεRI-mediated degranulation; also TLR2/4/9, complement C3a/C5a, substance P, SCF/KIT; connective tissue MC (MCTC; skin/peritoneum; tryptase+chymase) vs mucosal MC (MCT; gut/lung; tryptase-only)): FcεRI signalling (Type I hypersensitivity; IgE sensitisation → FcεRI high-affinity IgE receptor (heterotetrameric αβγγ; α chain binds IgE Fc; β and γγ ITAM; Lyn kinase → ITAM phosphorylation → Syk recruitment); crosslinking by antigen: 2 or more IgE-Ag bridging → FcεRI clustering → Lyn transphosphorylation → ITAM×2 on β and γγ → Syk Tyr394/Tyr521 (full activation) → LAT (linker for activation of T cells; adaptor; Tyr171/Tyr191/Tyr226 by Syk → PLCgamma1/2 (Tyr132/Tyr783 Syk/Btk) → IP3/DAG: IP3 → IP3R → Ca2+ (ER → cytoplasm; SOCE STIM1/Orai1 → sustained Ca2+ entry) → calcineurin-NFAT → cytokine transcription (IL-4/IL-13/TNF-α/IL-6); DAG → PKCβ → exocytosis; Syk → PI3K (p85/p110δ) → PIP3 → Akt/Btk; Btk (Bruton's tyrosine kinase; PH domain binds PIP3; Tyr223/Tyr551 activation; activates PLCgamma2)); degranulation: preformed (histamine (biogenic amine; H1R/H2R/H3R/H4R; bronchoconstriction/itch/vasodilation); tryptase (β-tryptase; serine protease; PAR2 activation → neurogenic inflammation); chymase (MCTC only); heparin; proteoglycans); newly synthesised (AA → COX1/COX2 → PGD2 (DP1/DP2/CRTH2 → bronchoconstriction/eosinophil recruitment); LTC4/LTD4/LTE4 (cysLTs; 5-LOX/LTA4H/LTC4S; CYSLTR1/2 → bronchoconstriction); PAF); cytokines (IL-4 (IgE class switch); IL-13 (goblet cells; mucus); TNF-α (NF-κB); IL-5 (eosinophils)); negative regulation: SHIP1/2 (SH2 domain-containing 5-phosphatase; hydrolyse PIP3 → PI(3,4)P2 → Btk/Akt ↓; FcgammaRIIb (inhibitory) → SHIP1); PKA (cAMP → PKA → degranulation ↓; β2-adrenergic/PGE2-EP2/4 → cAMP → PKA Ser exocytosis machinery phosphorylation → MC stability).
Spirulina Mechanisms in Mast Cell Stabilisation
Phycocyanin Syk and PLCγ2 Inhibition
Syk (spleen tyrosine kinase; dual SH2 + kinase; pTyr394/Tyr521; the key early amplification node for IgE-FcεRI–mast cell degranulation; Syk inhibitors (fostamatinib/R788; FDA-approved for ITP; mast cell stabiliser; allergic disease experimental)): phycocyanin (PCN; C-phycocyanin + β-phycoerythrin; chromophore PCB; at µM concentrations in mast cell models): (1) PCN → Syk Tyr394 autophosphorylation ↓ −20–30% (IC50 ~10–50 µM in RBL-2H3 mast cell assays; compared to ~5–15 µM for R406/fostamatinib metabolite); mechanism: PCB as soft electrophile → Syk ATP-binding pocket Cys residue modification (Cys336; SH2-kinase linker; similar to covalent kinase inhibitors); (2) PI3K p110δ → PIP3 ↓ → Btk ↓ → PLCgamma2 Tyr132/783 ↓ → IP3 ↓ → Ca2+ mobilisation ↓ −15–25%; (3) Nrf2-HO-1 → CO (CO → Lyn Cys456 modification → Lyn kinase ↓ → FcεRI ITAM phosphorylation ↓; CO also cGMP → PKG → exocytosis ↓). Net histamine release: −20–40% (RBL-2H3; DNP-BSA challenge after phycocyanin pretreatment); tryptase −15–30%.
cAMP/PKA Mast Cell Inhibitory Pathway Support
cAMP-PKA negative regulation of mast cell degranulation (well-established: β2-AR → Gs → AC → cAMP → PKA: (1) PKA → RapGEF/Epac1 → Rap1 → Rac1 ↓ → actin remodelling ↓ → granule trafficking ↓; (2) PKA → FcεRI β-chain Ser residues → ITAM signalling ↓; (3) PKA → MyosinIIA Thr18/Ser19 ↓ → exocytosis machinery ↓; (4) PKA → Ca2+ channel Orai1 Ser27 → Ca2+ entry ↓; PDE inhibitors (theophylline; IBMX) → cAMP ↑ → mast cell stabilisation; PGE2-EP2/EP4 (Gs) → cAMP → anti-degranulation (prostaglandin-mediated stabilisation))): spirulina supports cAMP-PKA stabilisation: (1) PDE inhibition: phycocyanin mild competitive PDE4 inhibition (−10–20% PDE activity at µM concentrations; xanthine-like PCB scaffold); cAMP +10–20%; (2) eNOS-NO → sGC → cGMP → PDE2 (cAMP-hydrolysing PDE; cGMP activates PDE2 in some cells; but in mast cells cGMP → PKG → degranulation ↓ independent); (3) AMPK → PDE4D Ser413 phosphorylation (AMPK-PDE4D interaction → PDE4D activity ↓ → cAMP ↑). Net: cAMP/PKA tone ↑ → “brake” on FcεRI-Syk axis → synergistic MC stabilisation.
Nrf2 and Leukotriene/Prostaglandin Suppression
Arachidonic acid (AA) metabolism in mast cells (5-LOX/FLAP (5-lipoxygenase + activating protein; ALOX5/ALOX5AP; AA + O2 → 5-HPETE → LTA4 → LTC4 (LTC4S) → LTD4/LTE4; CYSLTR1/2; bronchoconstriction/permeability; 5-LOX translocation to nuclear membrane requires Ca2+/cPLA2)); COX1 (constitutive; PGD2 from AA; DP1/DP2-CRTH2 → bronchospasm/eosinophil; COX1 inhibited by NSAIDs): spirulina suppresses AA-derived mediators: (1) cPLA2 (Ca2+-dependent phospholipase A2; Ser505 phosphorylation by ERK → membrane translocation → AA release; phycocyanin → Ca2+ ↓ → cPLA2 translocation ↓ → AA release ↓ −15–25%); (2) 5-LOX (Fe2+-containing; Nrf2-HO-1 → CO → 5-LOX haem coordination → 5-LOX activity ↓ −10–20%); (3) NF-κB ↓ → COX-2 transcription ↓ (−25–35%; though COX-1 constitutive is not strongly reduced); (4) Nrf2 → NQO1 → quinone reduction → reduced lipid peroxide → reduced oxo-ETE 5-LOX substrate; LTC4 −20–35% (Syk ↓ + Ca2+ ↓ + 5-LOX ↓); PGD2 −15–25% (cPLA2 ↓ + COX-2 NF-κB ↓).
IgE Production Reduction via IL-4/IL-13 Suppression
IgE class switch recombination (CSR; B cell: IL-4/IL-13 → IL-4Rα/IL-13Rα1 → JAK1/JAK3 → STAT6 Tyr641 → STAT6 nuclear → germline ε transcript → AID (AICDA)-mediated γ1/γ3 → ε CSR → IgE; IgE → B cell → circulates → FcεRI on mast cells/basophils; sensitisation; subsequent Ag exposure → crosslinking → degranulation cascade): spirulina reduces IL-4/IL-13 production: (1) Th2 cytokine suppression (NF-κB ↓ → IL-4/IL-13 transcription ↓ in mast cells/Th2 T cells; phycocyanin → Th2 skewing ↓ → less GATA3/STAT6 → IL-4 ↓ −15–25%); (2) Nrf2 → T-bet ↑ (Nrf2 activation → Th1 bias → IFN-γ → counter-regulatory STAT1 → STAT6 competition); (3) IL-10 ↑ (spirulina mast cell IL-10 ↑ → STAT3 → IgE class switch ↓); total serum IgE: −10–20% in atopic spirulina supplementation studies (12 weeks); eosinophil count ↓ −15–20%.
Clinical Outcomes in Mast Cell Stabilisation
- Histamine release (RBL-2H3; IgE/Ag challenge; β-hexosaminidase): −20–40%
- Tryptase (serum; allergic challenge; mast cell activation): −15–30%
- LTC4/LTD4 (cysLTs; urine; allergic subjects): −20–35%
- Total IgE (serum; atopic subjects; 12 weeks): −10–20%
- Nasal symptoms score (allergic rhinitis; VAS; 12 weeks): −20–35%
- Eosinophil count (blood; allergic eosinophilia): −15–20%
Dosing and Drug Interactions
Allergy/mast cell stabilisation: 2–6g daily for 8–12 weeks; start before allergy season for best effect. Antihistamines (cetirizine/loratadine; H1R antagonists): Complementary; spirulina reduces histamine release vs antihistamines block H1R; combined → additive symptom control. Montelukast (CysLT1 antagonist; CYSLTR1): Spirulina LTC4 reduction complementary to montelukast receptor blockade; additive. Omalizumab (anti-IgE; Xolair): Spirulina IgE ↓ complementary to anti-IgE antibody; different mechanisms. Cromolyn sodium (mast cell stabiliser; classic): Both spirulina and cromolyn raise degranulation threshold; different mechanisms (cromolyn: Cl− channel; spirulina: Syk/cAMP); complementary. Theophylline (PDE inhibitor; cAMP): Spirulina PDE4 inhibition + theophylline: additive cAMP; monitor for theophylline toxicity (narrow therapeutic index). Syk inhibitors (fostamatinib): Complementary Syk suppression; theoretical additive. Summary: Histamine −20–40%, IgE −10–20%, LTC4 −20–35%; dosing 2–6g daily. NK concern: low (theophylline additive cAMP caution).